PTPN11 and neoplasm: It has been shown to SHP2 promotes SPRY2 mRNA expression and inhibits its activity by dephosphorylating SPRY2 during the post‐translational phase in lens and lacrimal gland development; however, there is no such evidence in tumor cells so far.